Abstract 15110: The Effect of Drug-Eluting Stents on Clinical and Angiographic Outcomes in Renal Failure Patients with Dialysis: Multicenter Registry in Asia
Background: Patients treated with renal failure have been reported having high incidence of mortality and other complications rate after PCI. Optimal treatment of PCI for renal failure patients with dialysis is still unknown. Aim: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of percutaneous coronary intervention in renal failure patients with dialysis (CRF-HD).
Methods: A prospective analysis of 1013 patients with CRF-HD (258 SES, 244 PES, 77 ECS, 118 ZES-R, 128 BES, 188 EES) in six high volume Asian centers after successful stenting was performed. The study endpoints were 30 days major adverse cardiac events (MACE) and 12, 24 and 36 months target lesion revascularization (TLR) and MACE.
Results: The baseline clinical characteristics between 5 groups were similar. See table for clinical results.
Conclusion: The use of drug-eluting stents in patient with CRF-HD was safe with low acute complication. Patients treated with PES and EES showed lesser incidence of restenosis rate and TLR compared with other drug-eluting stents.
- © 2012 by American Heart Association, Inc.